Appendix II: Pharmaceutical Product Reporting Form (Part I) And Recall Notification Form (Part II)

Note:

Part I of this form should be used to report a problem with medicines and allied substances in quality, safety or efficacy, which are thought to have arisen during their manufacture, storage, or handling. Problems of this nature may require laboratory investigation by ZAMRA.

Part II of this form should be completed when a decision of recall is established.

When the reported problem may lead to a Class I or II recall, it should be reported to the Authority by telephone within 24 hours, and followed by email or letter of Part I of this form.

If a Class I or II recall is required, parts I and II of this form should be reported to the Authority immediately by telephone and followed by email or letter.

The manufacturer, marketing authorisation holder, local responsible person, distributor or importer should submit the available information to the Authority as soon as the recall decision is made, rather than waiting until ALL applicable information in part II is this form available.

For a problem that may lead to a Class III recall, Part I of this form should be reported to the Authority by letter or email within 72 hours.

If Class III recall is required, Parts I and II of this form should be submitted by letter or email to the Authority.

Contact information for the Authority:

The Director General Zambia Medicines Regulatory Authority Plot No. 2350/M Off Kenneth Kaunda International Airport PO Box 31890 Lusaka, Zambia Tel: +260 211 432 350 / 432 351 Email: <u>pharmacy@zamra.co.zm</u> Use a separate form for each pharmaceutical product reported.

Pharmaceutical Product Problem Report Form (Part I)

	DETAILS OF THE PROBLEM				
Reporting company:					
Name of contact pers	on:	Position:			
Name of the organisa	tion				
Address:					
Email:					
Telephone (office):		Mobile:			
Pharmaceutical prod problem:	luct problem occurre	ed in Zambia? If not, locat	ion of the		
Nature of the problem	n:				
Date of complaint rec	ceived:				
Source of complaint	Patient c self-inspection	ustomer 🗆	retailer 🗆		
	Other (specify)				
Number of similar rep	ports received:				
Description of the problem (use separate sheet if this space is not enough)					
Results of tests/Investigation on the suspect product or other samples					
Has the manufacturer or distributor been contacted? Yes \square No \square (If yes, please provide company names)					

Other relevant information	ı (Attach	photo,	package	insert,	and	press	release	of
any overseas authority of t	he produ	ct if any	7)					

DETAILS OF THE PRODUCT								
Name of the product (on marketing authorisation certificate)				ZA	MRA MA Nu	mber:		
Active ingredient and strength:								
Indications (Attach additional sheet if this space is not enough):								
Dosage			form	n:	Pa	ck size:		
Batch number:	-				Ex	piry date:		
Distribution of products:	Wholesale			Но	spitals 🗆	Health ce	enters	
		rmac				Drug stores 🗆 Health sho		ps 🗆
	Clin	ics 🗆			Others (specify)			
Manufacturer								
Name:								
Address:								
Tel (office): Em		Ema	Email:		Manufacture date:			
Batch size: Quant			Quantitie	es o	of batches manufactures:			
Date and quantity released:				Qu	uantity on hold:			
Quantity distributed:				Local:				
			Overseas:					
Importer								
Name:								
Address:								
Tel (office): Emai		ail:			Import date	2:		

Quantity of batch imported:	Quantity on hold:				
Date and quantity released					
Quantity distributed:	Local:				
	Re-exported:				
Local distributor (please attach distribution list)					
No. of local distributors:					
Name:					
Address:					
Contact person:	Tel (office):				
	Tel (mobile):				
Quantity on hold:	Quantity distributed:				
Exporter					
Has the product been exported? YES D NO D If yes, specify the country/countries:					
Name of Reporter	Position				
Contact Number Date					

Signature of the reporter

Recall Notification Form (Part II)

F	RISK ASSESSMENT					
Types of Hazards: Quality Safety Efficacy						
Other \Box (specify)						
	(*		·1 ·1· · · · · · · · · · · · · · · · ·			
Evaluation of hazards to user (Attach expert advice where app			sers, possibility of occurrence)			
(Attach expert advice where ap)	рпсаыс	<)				
Proposed recall classification: C	Class I a	🗆 Class II 🗆 (Class III 🗆			
Proposed action (with agreemen	nt of ZA	MRA)				
Recall start date:		Proposed re	ecall end date:			
Hotline(s) for inquiries:	1					
Hotline(s) hours of operation:	Mon-F	ri:	Sat, Sun, public holiday:			
Person responsible for recall:			Tel (Office):			
			Tel (Mobile):			
Proposed level of recall: Wholes						
Locations of recall spots (Custo	omer lev	vel recall onl	y):			
Means of refund at recall spots	: Cash	Replaceme	ent 🗆			
Other (specify)						
Proposed recall strategy (use se	eparate	sheet if this	space is not enough)			
Name of Reporter	•••••	Positio	n			

Contact Number Date

Signature of the reporter

Appendix III: Customer Reply Form

То	
Attention	
Email	
Postal Address	
Subject	
From	
Contact Person	
Telephone (office)	
Email	

We **DO** \square **DO NOT** \square have stock that is subject to this recall.

We have reported and returned all the stock on hand to

(Supplier)

Stock Received:

Batch No.	Quantity		

Unused stock subject to recall (currently in quarantine)

Batch No.	Quantity

Any	other	relevant	details:
	• • • • • • • • • • • • • • • • • • • •		•••••
	• • • • • • • • • • • • • • • • • • • •	•••••••••••••••••••••••••••••••••••••••	••••
••••••	• • • • • • • • • • • • • • • • • • • •	•••••••••••••••••••••••••••••••••••••••	••••

I declare that the information provided by me in this reply form is complete and true to the best of my knowledge.

Signature Date

DETAILS OF RECAL	LED PRODUCT			
Product name:	Marketing Authorisation No.:			
Active ingredient and strength:				
Dosage form:	Package size:			
Batch No.:	Expiry date:			
Reason for recall:				
Extent of distribution:				
Imported/manufactured quantity:				
Quantity distributed in Zambia:	No. of consignees:			
Quantity exported:	Countries:			
Action taken by the product owner (i.e., MA	H, LRP, importer, distributor etc.)			
Result of recall:				
Returned quantity:	Outstanding quantity:			
Used or sold quantity by the consignees:				
Quantity of stock not located:				
No. of recall reply forms received returned/reported:	from consignees and all stock			
Disposal plan: Destroy 🗆 Return to overseas	s manufacturer □ Other □ (Specify)			
Details of disposal method:				
Name of reporter Po	osition			
Contact Number D	Pate			

Appendix IV: Post Recall Report Form (Final Report)

Signature of the reporter

Appendix V: Document Related to Submission of Analytical Report

Accredited Test

The laboratory performing the tests should obtain accreditation on the specific test method in accordance with the international standards, e.g., ISO 17025. The Licensee shall submit the raw data and quality control data for the tested samples to substantiate the validity of test results. These data could facilitate the evaluation of the test result by the ZAMRA.

Non-Accredited Test

In case accreditation of the specific test could not be arranged, the analytical report might be considered acceptable if the laboratory has obtained appropriate accreditation in the area of pharmaceuticals or pharmaceutical products, and be able to provide necessary documentation to prove its competence in respect to its quality control and technical aspects in performance of the specific chemical tests.

Basically, the information should include, but is not limited to, the following:

- Detailed method (including standard preparation procedure, sample preparation procedure, instrument parameters, and quality control procedure);
- Raw data and quality control data for all tested samples shown in the report (including chromatograms, mass spectra and calculation);
- Validation summary for the method used (including method linearity, limit of detection, limit of quantitation, method bias, precision, and measurement uncertainty);
- Reference material used and purity verification summary; and
- Relevant proficiency test participation.